Curis

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Curis reports reduced losses, positive clinical data drive growth prospects

Curis demonstrated improved financial performance, strengthened by successful fundraising and promising clinical data, positioning the company for future growth.
While facing challenges in regulatory processes and balancing expenses, Curis remains focused on innovation and market opportunities to drive value creation.
Investors should monitor Curis' upcoming presentations and regulatory developments closely, as positive outcomes could significantly impact the company's trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blink Charging

Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)

Curis (CRIS) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.

Curis (CRIS) Surges: Stock Moves 5% Higher

Curis Inc. (NASDAQ: CRIS) shares are on the run again.

The Hits Keep Coming With Curis's Secondary Offering

LEXINGTON, Mass., Dec. 9, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a...

Curis Announces Pricing of Public Offering of Common Stock

Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.

Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates

The stock price of Curis, Inc. (NASDAQ: CRIS) increased by 354.86% as it went from a previous close of $1.44 to $6.55 per share today. This is why it happened.

Curis Stock Price Increases 354.86%: Why It Happened

Curis, Inc. staged an eye-popping rally on Tuesday after it released positive preliminary data related to its phase one trial of CA-4948, a small molecule inhibitor that is being tested in patients with acute myeloid leukemia. Curis shares jumped as much as 448% in Tuesday trades to $7.90. The stock closed at $1.44 on Monday.

Curis skyrockets 448% after encouraging phase 1 data for leukemia treatment (CRIS)

Stitch Fix

Further gains for the top stock market came from big movers.

Stitch Fix Helps Nasdaq Stretch Toward Records; Curis Erupts Higher

Curis, Inc. (NASDAQ: CRIS) shares were skyrocketing Tuesday on above-average volume after the company announced updated Phase 1 data on its investigational asset CA-4948 in treating acute myeloid leukemia and myelodysplastic syndromes.  What Happened: As of Nov. 23, four AML and three high-risk MDS patients were enrolled in the first two study cohorts of the Phase 1 study that evaluated CA-4948, a small-molecule IRAK4 kinase inhibitor, the company said, citing preliminary data.

Curis Surges 330% On Early Stage Blood Cancer Data

Curis (CRIS) stock is taking off on Tuesday following news of positive preliminary data from a Phase 1 clinical trial for its leukemia drug. The post CRIS Stock News: Why Biotech Stock Play Curis Is Going Gangbusters appeared first on InvestorPlace.

CRIS Stock News: Why Biotech Stock Play Curis Is Going Gangbusters

After Curis Inc. (NASDAQ: CRIS) announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS), its shares absolutely exploded higher on Tuesday.

This Curis Cancer Study Is a Big Hit

Shares of Curis Inc. more than tripled Tuesday, to lead all premarket gainers and with the most volume, after the biotechnology company announced positive preliminary data from a Phase 1 study of its leukemia treatment. The stock skyrocketed 256.3%, putting them on track to open at the highest price seen during regular-session hours since March 2018.

Curis stock more than triples on massive volume after upbeat leukemia treatment trial results

LEXINGTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated data from its ongoing Phase 1, open-label, dose escalation study of CA-4948, an...

Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Curis, Inc. (CRIS) CEO Jim Dentzer on Q3 2020 Results - Earnings Call Transcript

Curis, Inc. (CRIS) CEO Jim Dentzer On Q3 2020 Results - Quick Version Earnings Call Transcript

Shares of Curis (NASDAQ:CRIS) fell 0.88% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 42.11% year over year to ($0.11), which beat the estimate of ($0.13).

Curis: Q3 Earnings Insights

LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that three abstracts for CA-4948, a small molecule IRAK4 inhibitor, have been accepted for...

Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C....

Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference

LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a paper published online in ACS Medicinal Chemistry Letters, a peer-reviewed publication...

Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies

LEXINGTON, Mass., Oct. 14, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a Trial in Progress abstract for CI-8993, a first-in-class monoclonal anti-VISTA...

Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2020 Results - Earnings Call Transcript

The Only Way To Play Curis

LEXINGTON, Mass., June 11, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into definitive agreements with fundamental healthcare investors for...

Curis Announces $17.5 Million Registered Direct Offering

Shares of nano-cap biopharma Curis, Inc. (NASDAQ: CRIS) are on a strong two-day run that has lifted the equity from penny stock territory.

The 'Important Step' For Nano-Cap Biopharma Curis That's Sending Shares Higher

Curis Inc. (NASDAQ: CRIS) shares jumped on Wednesday after the company announced that the U.S.

News for Curis Stock (CRIS)